Aclaris Amends 8-K on Executive Changes, Compensation
Ticker: ACRS · Form: 8-K/A · Filed: Feb 5, 2024 · CIK: 1557746
| Field | Detail |
|---|---|
| Company | Aclaris Therapeutics, INC. (ACRS) |
| Form Type | 8-K/A |
| Filed Date | Feb 5, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.00001, $500,000, $1.20 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: executive-changes, compensation, amendment
TL;DR
**Aclaris filed an amended 8-K about executive changes and pay, watch for details.**
AI Summary
Aclaris Therapeutics, Inc. filed an 8-K/A on February 5, 2024, amending its previous report from January 15, 2024. This amendment clarifies information regarding the departure or election of directors or officers and their compensatory arrangements. This matters to investors because changes in executive leadership and their compensation can signal shifts in company strategy or financial health, potentially impacting future stock performance.
Why It Matters
Changes in executive leadership and their compensation can significantly influence a company's strategic direction and operational stability, directly affecting investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — While an amendment itself isn't inherently risky, the underlying executive changes and compensation details it clarifies could introduce uncertainty or signal strategic shifts.
Analyst Insight
A smart investor would monitor subsequent filings or company announcements for the specific details of the executive changes and compensation arrangements that this 8-K/A is clarifying, as these details could impact future company performance and stock valuation.
Key Players & Entities
- Aclaris Therapeutics, Inc. (company) — the registrant filing the 8-K/A
- January 15, 2024 (date) — date of the earliest event reported in the original 8-K
- February 5, 2024 (date) — date the 8-K/A amendment was filed
- Nasdaq Stock Market, LLC (company) — exchange where Aclaris's common stock is registered
FAQ
What is the purpose of this 8-K/A filing by Aclaris Therapeutics, Inc.?
This 8-K/A (Amendment No. 1) is filed to amend a previous Current Report on Form 8-K, specifically concerning 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' as per the Item Information.
What was the original date of the earliest event reported that this amendment refers to?
The original date of the earliest event reported was January 15, 2024, as stated in the 'Date of Report (Date of earliest event reported)' section.
When was this amendment (8-K/A) filed with the SEC?
This amendment was filed on February 5, 2024, as indicated by the 'FILED AS OF DATE' and 'ACCESSION NUMBER' information.
What is the trading symbol and exchange for Aclaris Therapeutics, Inc.'s common stock?
Aclaris Therapeutics, Inc.'s common stock trades under the symbol 'ACRS' on The Nasdaq Stock Market, LLC, as listed under 'Securities registered pursuant to Section 12(b) of the Act'.
What specific items of the Form 8-K are being addressed by this amendment?
The amendment addresses Item 5.02, which covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'.
Filing Stats: 1,143 words · 5 min read · ~4 pages · Grade level 12.1 · Accepted 2024-02-05 16:31:05
Key Financial Figures
- $0.00001 — ange on which Registered Common Stock, $0.00001 par value ACRS The Nasdaq Stock Mar
- $500,000 — r will receive an annual base salary of $500,000 and will be eligible to receive a cash
- $1.20 — common stock with an exercise price of $1.20 per share, which was the closing price
Filing Documents
- acrs-20240115x8ka.htm (8-K/A) — 44KB
- 0001558370-24-000770.txt ( ) — 163KB
- acrs-20240115.xsd (EX-101.SCH) — 3KB
- acrs-20240115_lab.xml (EX-101.LAB) — 16KB
- acrs-20240115_pre.xml (EX-101.PRE) — 10KB
- acrs-20240115x8ka_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ACLARIS THERAPEUTICS, INC. By: /s/ Kevin Balthaser Date: February 5, 2024 Kevin Balthaser Chief Financial Officer